Lifecore Biomedical (LFCR) 10-Q 9 Jan 15 2015 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Nov. 30, 2014	Dec. 26, 2014
Entity Registrant Name	LANDEC CORP \CA\
Entity Central Index Key	1005286
Current Fiscal Year End Date	-26
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		26,875,984
Document Type	10-Q
Document Period End Date	30-Nov-14
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Amendment Flag	FALSE

Consolidated_Balance_Sheets_Cu

Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Nov. 30, 2014	25-May-14
In Thousands, unless otherwise specified
Current Assets:
Cash and cash equivalents	$4,970	$14,243
Accounts receivable, less allowance for doubtful accounts of $415 and $516 at November 30, 2014 and May 25, 2014, respectively	52,136	44,421
Accounts receivable, related party	162	304
Income taxes receivable	156	2,000
Inventories, net	30,440	24,735
Deferred taxes	1,985	2,056
Prepaid expenses and other current assets	5,095	3,170
Total Current Assets	94,944	90,929
Investment in non-public company, non-fair value	793	793
Investment in non-public company, fair value	59,000	39,600
Property and equipment, net	78,375	74,140
Goodwill, net	49,620	49,620
Trademarks/tradenames, net	48,428	48,428
Customer relationships, net	8,277	8,720
Other assets	1,662	1,393
Total Assets	341,099	313,623
Current Liabilities:
Accounts payable	39,184	31,981
Accounts payable, related party	332	134
Accrued compensation	4,973	4,096
Other accrued liabilities	4,939	4,871
Deferred revenue	211	1,254
Lines of credit	5,000
Current portion of long-term debt	7,550	6,055
Total Current Liabilities	62,189	48,391
Long-term portion	34,675	28,317
Deferred taxes	31,477	30,133
Other non-current liabilities	1,650	2,021
Total Liabilities	129,991	108,862
Stockholders’ Equity:
Common stock, $0.001 par value; 50,000,000 shares authorized; 26,875,984 and 26,815,253 shares issued and outstanding at November 30, 2014 and May 25, 2014, respectively	27	27
Additional paid-in capital	132,360	131,488
Retained earnings	77,130	71,554
Total Stockholders’ Equity	209,517	203,069
Non-controlling interest	1,591	1,692
Total Equity	211,108	204,761
Total Liabilities and Stockholders’ Equity	$341,099	$313,623

Consolidated_Balance_Sheets_Cu1

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Nov. 30, 2014	25-May-14
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$415	$516
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	26,875,984	26,815,253
Common stock, shares outstanding (in shares)	26,875,984	26,815,253

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Unaudited) (USD $)	3 Months Ended		6 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Nov. 30, 2014	Nov. 24, 2013	Nov. 30, 2014	Nov. 24, 2013
Revenue	$132,665,000	$120,026,000	$266,279,000	$229,505,000
Cost of product sales	116,999,000	106,292,000	236,425,000	203,239,000
Gross profit	15,666,000	13,734,000	29,854,000	26,266,000
Operating costs and expenses:
Research and development	1,825,000	1,919,000	3,620,000	3,845,000
Selling, general and administrative	9,949,000	8,639,000	18,808,000	17,269,000
Total operating costs and expenses	11,774,000	10,558,000	22,428,000	21,114,000
Operating income	3,892,000	3,176,000	7,426,000	5,152,000
Dividend income	321,000	281,000	602,000	563,000
Interest income	91,000	46,000	184,000	105,000
Interest expense	-472,000	-436,000	-855,000	-867,000
Other income	1,200,000	2,300,000	1,400,000	7,700,000
Net income before taxes	5,032,000	5,367,000	8,757,000	12,653,000
Income tax expense	-1,785,000	-1,874,000	-3,086,000	-4,349,000
Consolidated net income	3,247,000	3,493,000	5,671,000	8,304,000
Non-controlling interest	-24,000	-42,000	-95,000	-101,000
Net income and comprehensive income applicable to common stockholders	$3,223,000	$3,451,000	$5,576,000	$8,203,000
Basic net income per share (in dollars per share)	$0.12	$0.13	$0.21	$0.31
Diluted net income per share (in dollars per share)	$0.12	$0.13	$0.20	$0.30
Earnings Per Share [Abstract]
Basic (in shares)	26,864	26,571	26,852	26,512
Diluted (in shares)	27,314	27,070	27,293	27,081

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Nov. 30, 2014	Nov. 24, 2013
Cash flows from operating activities:
Consolidated net income	$5,671,000	$8,304,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,343,000	3,787,000
Stock-based compensation expense	748,000	639,000
Tax benefit from stock-based compensation expense	-36,000	-175,000
Net loss on disposal of property and equipment		124,000
Deferred taxes	1,415,000	4,050,000
Change in investment in non-public company, fair value	-1,400,000	-7,700,000
Changes in current assets and current liabilities:
Accounts receivable, net	-7,715,000	-5,673,000
Accounts receivable, related party	142,000	540,000
Income taxes receivable	1,880,000	262,000
Inventories, net	-5,705,000	-2,752,000
Issuance of notes and advances receivable	-2,464,000
Collection of notes and advances receivable	363,000
Prepaid expenses and other current assets	176,000	-1,361,000
Accounts payable	7,203,000	3,049,000
Accounts payable, related party	198,000	-544,000
Accrued compensation	877,000	-743,000
Other accrued liabilities	-303,000	2,452,000
Deferred revenue	-1,043,000	34,000
Net cash provided by operating activities	3,350,000	4,293,000
Cash flows from investing activities:
Purchases of property and equipment	-7,135,000	-7,681,000
Investment in non-public company, fair value	-18,000,000
Purchase of marketable securities		-1,417,000
Net cash used in investing activities	-25,135,000	-6,136,000
Cash flows from financing activities:
Proceeds from sale of common stock	100,000	1,253,000
Taxes paid by Company for stock swaps and RSUs	-12,000	-1,219,000
Tax benefit from stock-based compensation expense	36,000	175,000
Proceeds from long-term debt	11,194,000
Payments on long-term debt	-3,341,000	-3,128,000
Proceeds from lines of credit	25,117,000
Payments on lines of credit	-20,117,000	-3,000,000
Change in other assets	-269,000	36,000
Distributions to non-controlling interest	-196,000	-226,000
Net cash provided by (used in) financing activities	12,512,000	-6,109,000
Net decrease in cash and cash equivalents	-9,273,000	-7,952,000
Cash and cash equivalents at beginning of period	14,243,000	13,718,000
Cash and cash equivalents at end of period	4,970,000	5,766,000
Marketable Maturities [Member]
Cash flows from investing activities:
Proceeds from maturities of marketable securities		$2,962,000

Note_1_Organization_Basis_of_P

Note 1 - Organization, Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1	Organization, Basis of Presentation and Summary of Significant Accounting Policies
	Organization
	Landec Corporation and its subsidiaries (“Landec” or the “Company”) design, develop, manufacture and sell differentiated products for food and biomaterials markets and license technology applications to partners. The Company has two proprietary polymer technology platforms: 1) Intelimer® polymers, and 2) hyaluronan (“HA”) biopolymers. The Company sells specialty packaged branded Eat Smart® and GreenLine® and private label fresh-cut vegetables and whole produce to retailers, club stores and foodservice operators, primarily in the United States, Canada and Asia through its Apio, Inc. (“Apio”) subsidiary and sells HA-based biomaterials through its Lifecore Biomedical, Inc. (“Lifecore”) subsidiary. The Company’s HA biopolymers are proprietary in that they are specially formulated for specific customers to meet strict regulatory requirements.
	The Company’s polymer technologies, along with its customer relationships and trade names, are the foundation, and a key differentiating advantage upon which Landec has built its business.
	Basis of Presentation
	The accompanying unaudited consolidated financial statements of Landec have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring accruals) have been made which are necessary to present fairly the financial position at November 30, 2014, and the results of operations and cash flows for all periods presented. Although Landec believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements and related footnotes prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission. The accompanying financial data should be reviewed in conjunction with the audited financial statements and accompanying notes included in Landec's Annual Report on Form 10-K for the fiscal year ended May 25, 2014.
	The results of operations for the six months ended November 30, 2014 are not necessarily indicative of the results that may be expected for an entire fiscal year because there is some seasonality in Apio’s food business, particularly, Apio’s Food Export business and the order patterns of Lifecore’s customers which may lead to significant fluctuations in Landec’s quarterly results of operations. In addition, the first quarter of fiscal year 2015 was a 14-week quarter which occurs once every six years compared to the standard 13-week quarter.
	Basis of Consolidation
	The consolidated financial statements are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States and include the accounts
	of Landec Corporation and its subsidiaries, Apio and Lifecore. All material inter-company transactions and balances have been eliminated.
	Arrangements that are not controlled through voting or similar rights are reviewed under the guidance for variable interest entities (“VIEs”). A company is required to consolidate the assets, liabilities and operations of a VIE if it is determined to be the primary beneficiary of the VIE.
	An entity is a VIE and subject to consolidation, if by design: a) the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support provided by any parties, including equity holders or b) as a group the holders of the equity investment at risk lack any one of the following three characteristics: (i) the power, through voting rights or similar rights to direct the activities of an entity that most significantly impact the entity’s economic performance, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity. The Company reviewed the consolidation guidance and concluded that its partnership interest in Apio Cooling and its equity investments in non-public companies are not VIEs.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; sales returns and allowances; self insurance liabilities; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived assets; the valuation of intangible assets and inventory; the valuation of investments; and the valuation and recognition of stock-based compensation.
	These estimates involve the consideration of complex factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and is subject to change from period to period. The actual results may differ from management’s estimates.
	Cash and Cash Equivalents
	The Company records all highly liquid securities with three months or less from date of purchase to maturity as cash equivalents. Cash equivalents consisted of money market funds of $1.5 million at both November 30, 2014 and May 25, 2014. The market value of cash equivalents approximates their historical cost given their short-term nature.
	Financial Instruments
	The Company’s financial instruments are primarily composed of marketable securities, commercial-term trade payables, grower advances, notes receivable and debt instruments. For short-term instruments, the historical carrying amount approximates the fair value of the instrument. The fair value of long-term debt and lines of credit approximates their carrying value. Fair values for long-term financial instruments not readily marketable are estimated based upon discounted future cash flows at prevailing market interest rates. Based on these assumptions, management believes the fair values of the Company’s financial instruments are not materially different from their recorded amounts as of November 30, 2014 and May 25, 2014.
	Investments in Non-Public Companies
	The Company’s investment in Aesthetic Sciences Corporation (“Aesthetic Sciences”), which is reported as an investment in non-public company, non-fair value, in the accompanying Consolidated Balance Sheets, is carried at cost and adjusted for impairment losses. Since there is no readily available market value information, the Company periodically reviews this investment to determine if any other than temporary declines in value have occurred based on the financial stability and viability of Aesthetic Sciences.
	On February 15, 2011, Apio purchased 150,000 senior preferred shares for $15 million and 201 common shares for $201 that were issued by Windset Holdings 2010 Ltd., a Canadian corporation (“Windset”). On July 15, 2014, Apio increased its investment in Windset by purchasing an additional 68 shares of common stock and 51,211 shares of junior preferred stock of Windset for $11.0 million. On October 29, 2014, Apio purchased an additional 70,000 senior preferred shares of Windset for $7.0 million. These investments are reported as an investment in non-public company, fair value, in the accompanying Consolidated Balance Sheets as of November 30, 2014 and May 25, 2014. The Company has elected to account for its investment in Windset under the fair value option (see Note 2).
	Intangible Assets
	The Company’s intangible assets are comprised of customer relationships with a finite estimated useful life of twelve to thirteen years and trademarks, trade names and goodwill with indefinite lives.
	Finite-lived intangible assets are reviewed for possible impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an asset (or asset group) may not be recoverable.  Indefinite lived intangible assets are reviewed for impairment at least annually. For non-goodwill indefinite-lived intangible assets, the Company performs a qualitative analysis in accordance with ASC 350-30-35. For goodwill, the Company has historically performed a quantitative analysis in accordance with ASC 350-20-35.
	Partial Self-Insurance on Employee Health Plan
	The Company provides health insurance benefits to eligible employees under a self-insured plan whereby the Company pays actual medical claims subject to certain stop loss limits. The Company records self-insurance liabilities based on actual claims filed and an estimate of those claims incurred but not reported. Any projection of losses concerning the Company's liability is subject to a high degree of variability. Among the causes of this variability are unpredictable external factors such as inflation rates, changes in severity, benefit level changes, medical costs, and claims settlement patterns. This self-insurance liability is included in accrued liabilities and represents management's best estimate of the amounts that have not been paid as of November 30, 2014 and May 25, 2014. It is reasonably possible that the expense the Company ultimately incurs could differ and adjustments to future reserves may be necessary.
	Long-Term Incentive Plan
	On July 25, 2013, the Landec Long-Term Incentive Plan (“LTIP”) was established which allows certain executives to earn a performance-based bonus that is based upon a cumulative operating income target for fiscal years 2014, 2015, and 2016. The LTIP was designed to align the interests of management with the long-term financial success of the Company. If the three-year cumulative operating income target had been met, approximately $2.0 million in bonuses would have been paid. Through fiscal year 2014, the Company was recording the estimated plan bonus on a straight-line basis over the 36-month LTIP period. As of August 31, 2014, the Company determined it was unlikely the three-year cumulative operating income target would be attained and therefore all LTIP bonus accruals were reversed at that date. The reversal resulted in a $677,000 reduction in selling, general, and administrative expenses during the six months ended November 30, 2014 in the accompanying Consolidated Statements of Comprehensive Income. The long-term incentive bonuses accrued under this plan of zero and $677,000 are included in other non-current liabilities in the accompanying Consolidated Balance Sheets as of November 30, 2014 and May 25, 2014, respectively.
	Fair Value Measurements
	The Company uses fair value measurement accounting for financial assets and liabilities and for financial instruments and certain other items measured at fair value. The Company has elected the fair value option for its investment in a non-public company (see Note 2). The Company has not elected the fair value option for any of its other eligible financial assets or liabilities.
	The accounting guidance established a three-tier hierarchy for fair value measurements, which prioritizes the inputs used in measuring fair value as follows:
	Level 1 – observable inputs such as quoted prices for identical instruments in active markets.
	Level 2 – inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.
	Level 3 – unobservable inputs in which there is little or no market data, which would require the Company to develop its own assumptions.
	As of November 30, 2014, the Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis, including an interest rate swap and a minority interest investment in Windset.
	The fair value of the Company’s interest rate swap is determined based on model inputs that can be observed in a liquid market, including yield curves, and is categorized as a Level 2 measurement.
	The Company has elected the fair value option of accounting for its investment in Windset. The calculation of fair value utilizes significant unobservable inputs, including projected cash flows, growth rates and discount rates. As a result, the Company’s investment in Windset is considered to be a Level 3 measurement investment. The change in the fair value of the Company’s investment in Windset for the six months ended November 30, 2014 was due to the Company’s 26.9% minority interest in the change in the fair market value of Windset during the period. In determining the fair value of the investment in Windset, the Company utilizes the following significant unobservable inputs in the discounted cash flow models:
			At November 30, 2014			At May 25, 2014
	Revenue growth rates			4%			4%
	Expense growth rates			4%			4%
	Income tax rates			15%			15%
	Discount rates			16% to 22%			16% to 22%
	The revenue growth, expense growth and income tax rate assumptions, consider the Company's best estimate of the trends in those items over the discount period.   The discount rate assumption takes into account the risk-free rate of return, the market equity risk premium and the company’s specific risk premium and then applies an additional discount for lack of liquidity of the underlying securities.    The discounted cash flow valuation model used by the Company has the following sensitivity to changes in inputs and assumptions (in thousands):
	Impact on value of Windset investment as of November 30, 2014
	10% increase in revenue growth rates		$	4,900
	10% increase in expense growth rates		$	(4,100	)
	10% increase in income tax rates		$	—
	10% increase in discount rates		$	(700	)
	Imprecision in estimating unobservable market inputs can affect the amount of gain or loss recorded for a particular position. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
	The following table summarizes the fair value of the Company’s assets and liabilities that are measured at fair value on a recurring basis, as of November 30, 2014 and May 25, 2014 (in thousands):
			Fair Value at November 30, 2014							Fair Value at May 25, 2014
			Level 1			Level 2		Level 3		Level 1		Level 2		Level 3
	Assets:
	Investment in private company			-			-		59,000		-		-		39,600
	Total		$	-		$	-	$	59,000	$	-	$	-	$	39,600
	Liabilities:
	Interest rate swap			-			9		-		-		44		-
	Total		$	-		$	9	$	-	$	-	$	44	$	-
	Revenue Recognition
	Revenue from product sales is recognized when there is persuasive evidence that an arrangement exists, title has transferred, the price is fixed and determinable, and collectability is reasonably assured. Allowances are established for estimated uncollectible amounts, product returns, and discounts based on specific identification and historical losses.
	Apio’s Food Products Technology revenues generally consist of revenues generated from the sale of specialty packaged fresh-cut and whole value-added processed vegetable products that are generally washed and packaged in the Company’s proprietary packaging and sold under Apio’s Eat Smart and GreenLine brands and various private labels. Revenue is generally recognized upon shipment of these products to customers. The Company takes title to all produce it trades and/or packages, and therefore, records revenues and cost of sales at gross amounts in the Consolidated Statements of Comprehensive Income
	In addition, Food Products Technology value-added revenues include the revenues generated from Apio Cooling, LP, a vegetable cooling operation in which Apio is the general partner with a 60% ownership position and from the sale of BreatheWay packaging to license partners. Revenue is recognized on the vegetable cooling operations as cooling and storage services are provided to the Company’s customers. Sales of BreatheWay packaging are recognized when shipped to the customer.
	Apio’s Food Export revenues consist of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia by Cal-Ex. As most Cal-Ex customers are in countries outside of the U.S., title transfers and revenue is generally recognized upon arrival of the shipment in the foreign port. Apio records revenue equal to the sale price to third parties because it takes title to the product while in transit.
The HA-based Biomaterials business principally generates revenue through the sale of products containing HA. Lifecore primarily sells products to customers in three medical areas: (1) Ophthalmic, which represented approximately 60% of Lifecore’s revenues in fiscal year 2014, (2) Orthopedic, which represented approximately 20% of Lifecore’s revenues in fiscal year 2014 and (3) Veterinary/Other. The vast majority of revenues from the Company’s HA-based Biomaterials business are recognized upon shipment.
A small amount of revenues from the HA-based Biomaterials business is related to contract research and development (R&D) services and multi-element arrangement services with customers where the Company provides products and/or services in a bundled arrangement.
Contract R&D revenue is recorded as earned, based on the performance requirements of the contract. Non-refundable contract fees for which no further performance obligations exist, and there is no continuing involvement by the Company, are recognized on the earlier of when the payment is received or collection is assured.
For sales arrangements that contain multiple elements, the Company splits the arrangement into separate units of accounting if the individually delivered elements have value to the customer on a standalone basis. The Company also evaluates whether multiple transactions with the same customer or related party should be considered part of a multiple element arrangement, whereby the Company assesses, among other factors, whether the contracts or agreements are negotiated or executed within a short time frame of each other or if there are indicators that the contracts are negotiated in contemplation of each other. The Company then allocates revenue to each element based on a selling price hierarchy. The relative selling price for a deliverable is based on its vendor-specific objective evidence (VSOE), if available, third-party evidence (TPE), if VSOE is not available, or estimated selling price, if neither VSOE nor TPE is available. The Company then recognizes revenue on each deliverable in accordance with its policies for product and service revenue recognition. The Company is not typically able to determine VSOE or TPE, and therefore, uses the estimated selling price to allocate revenue between the elements of an arrangement.
The Company limits the amount of revenue recognition for delivered elements to the amount that is not contingent on the future delivery of products or services or future performance obligations or subject to customer-specific cancellation rights. The Company evaluates each deliverable in an arrangement to determine whether it represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has stand-alone value, and for an arrangement that includes a general right of return relative to the delivered products or services, delivery or performance of the undelivered product or service is considered probable and is substantially controlled by the Company. The Company considers a deliverable to have stand-alone value if the product or service is sold separately by the Company or another vendor or could be resold by the customer. Further, the revenue arrangements generally do not include a general right of return relative to delivered products. Where the aforementioned criteria for a separate unit of accounting are not met, the deliverable is combined with the undelivered element(s) and treated as a single unit of accounting for the purposes of allocation of the arrangement consideration and revenue recognition. The Company allocates the total arrangement consideration to each separable element of an arrangement based upon the relative selling price of each element. Allocation of the consideration is determined at arrangement inception on the basis of each unit’s relative selling price. In instances where the Company has not established fair value for any undelivered element, revenue for all elements is deferred until delivery of the final element is completed and all recognition criteria are met.
Licensing revenue is recognized in accordance with prevailing accounting guidance. Initial license fees are deferred and amortized to revenue over the period of the agreement when a contract exists, the fee is fixed and determinable, and collectability is reasonably assured. Noncancellable, nonrefundable license fees are recognized over the period of the agreement, including those governing research and development activities and any related supply agreement entered into concurrently with the license when the risk associated with commercialization of a product is non-substantive at the outset of the arrangement.
From time to time, the Company offers customers sales incentives, which include volume rebates and discounts. These amounts are estimated on a quarterly basis and recorded as a reduction of revenue.
A summary of revenues by type of revenue arrangement as described above is as follows (in thousands):
		Three months			Three months		Six months		Six months
		ended			ended		ended		ended
		30-Nov			24-Nov		30-Nov		24-Nov
		, 2014			, 201		, 2014		, 201
					3				3
Recorded upon shipment		$	109,764		$	95,002	$	216,004	$	182,412
Recorded upon acceptance in foreign port			22,106			22,940		48,693		44,329
Revenue from license fees, R&D contracts and royalties/profit sharing			423			143		635		201
Revenue from multiple element arrangements			372			1,941		947		2,563
Total		$	132,665		$	120,026	$	266,279	$	229,505
New
Accounting Pronouncements
Revenue Recognition
In May 2014, the FASB issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"), which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a cohesive set of disclosure requirements intended to provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a company’s contracts with customers. ASU 2014-09 will be effective beginning the first quarter of the Company's fiscal year 2018 and early application is not permitted. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. Management is currently evaluating the effect ASU 2014-09 will have on the Company's Consolidated Financial Statements and disclosures.

Note_2_Investments_in_Nonpubli

Note 2 - Investments in Non-public Companies	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Investment Holdings [Text Block]	2	Investments in non-public companies
	In December 2005, Landec entered into a licensing agreement with Aesthetic Sciences for the exclusive rights to use Landec's Intelimer® materials technology for the development of dermal fillers worldwide under the agreement. The Company received shares of preferred stock in exchange for the license with a valuation of $1.8 million. Aesthetic Sciences sold the rights to its Smartfil™ Injector System on July 16, 2010. Landec has evaluated its investment in Aesthetic Sciences for impairment, utilizing a discounted cash flow analysis under the terms of the purchase agreement. Based on the terms of the sale, the Company determined that its investment was other than temporarily impaired and therefore, recorded an impairment charge of $1.0 million as of May 30, 2010. The Company’s carrying value of its investment in Aesthetic Sciences is $793,000 as of November 30, 2014 and May 25, 2014. No additional impairment has been determined for the Company’s investment in Aesthetic Sciences.
	On February 15, 2011, Apio entered into a share purchase agreement (the “Windset Purchase Agreement”) with Windset. Pursuant to the Windset Purchase Agreement, Apio purchased from Windset 150,000 Senior A preferred shares for $15 million and 201 common shares for $201. On July 15, 2014, Apio increased its investment in Windset by purchasing from the Newell Capital Corporation an additional 68 shares of common stock and 51,211 shares of junior preferred stock of Windset for $11.0 million. After this purchase, the Company’s common shares represent a 26.9% ownership interest in Windset. The non-voting Senior A preferred shares yield a cash dividend of 7.5% annually. The dividend is payable within 90 days of each anniversary of the execution of the Windset Purchase Agreement The non-voting junior preferred stock does not yield a dividend unless declared by the Board of Directors of Windset and no such dividend has been declared.
	The Windset Purchase Agreement includes a put and call option, which can be exercised on the sixth anniversary of the Windset Purchase Agreement whereby Apio can exercise the put to sell its common, Senior A preferred shares and junior preferred shares to Windset, or Windset can exercise the call to purchase those shares from Apio, in either case, at a price equal to 26.9% of the appreciation in the fair market value of Windset’s common shares from the date of the Company’s investment through the put and call date, plus the liquidation value of the preferred shares of $20.1 million ($15 million for the Senior A preferred shares and $5.1 million for the junior preferred shares).
	Under the terms of the arrangement with Windset, the Company is entitled to designate one of five members on the Board of Directors of Windset.
	On October 29, 2014, Apio further increased its investment in Windset by purchasing 70,000 shares of Senior B preferred shares. The Senior B Preferred Stock pays an annual dividend of 7.5% on the amount outstanding at each anniversary date of the Windset Purchase Agreement. The Senior B shares purchased by Apio have a put feature whereby Apio can sell back to Windset $1.5 million of shares on the first anniversary, an additional $2.75 million of shares on the second anniversary and the remaining $2.75 million on the third anniversary. After the third anniversary, Apio may at any time put any or all of the shares not previously sold back to Windset. At any time on or after February 15, 2017, Windset has the right to call any or all of the outstanding common shares and at such time must also call the same proportion of Senior A preferred shares, Senior B preferred shares and junior preferred shares owned by Apio. Windset’s partial call provision is restricted such that a partial call cannot result in Apio holding less than 10% of Windset’s common shares outstanding.
	The investment in Windset does not qualify for equity method accounting as the investment does not meet the criteria of in-substance common stock due to returns through the annual dividend on the non-voting senior preferred shares that are not available to the common stock holders. As the put and call options require the Purchased Shares to be put or called in equal proportions, the Company has deemed that the investment, in substance, should be treated as a single security for purposes of accounting.
	During the three months ended November 30, 2014 and November 24, 2013, the Company recorded $321,000 and $281,000, respectively, in dividend income. During the six months ended November 30, 2014 and November 24, 2013, the Company recorded $602,000 and $563,000, respectively, in dividend income. The change in the fair market value of the Company’s investment in Windset for the three months ended November 30, 2014 and November 24, 2013 was $1.2 million and $2.3 million, respectively, and is included in other income in the Consolidated Statements of Comprehensive Income. The change in the fair market value of the Company’s investment in Windset for the six months ended November 30, 2014 and November 24, 2013 was $1.4 million and $7.7 million, respectively, and is included in other income in the Consolidated Statements of Comprehensive Income.
	The Company also entered into an exclusive license agreement with Windset, which was executed in June 2010, prior to contemplation of Apio’s investment in Windset. The license agreement allows Windset the use of Landec’s proprietary breathable packaging to extend the shelf life of greenhouse grown cucumbers, peppers and tomatoes (“Exclusive Products”). In accordance with the agreement, Apio received and recorded a one-time upfront research and development fee of $100,000 and will receive license fees equal to 3% of net revenue of the Exclusive Products utilizing the
	proprietary breathable packaging technology, with or without the BreatheWay® trademark. The ongoing license fees are subject to annual minimums of $150,000 for each of the three types of exclusive product as each is added to the agreement. As of November 30, 2014, two products have been added to the agreement.

Note_3_Stockbased_Compensation

Note 3 - Stock-based Compensation	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	3	Stock-Based Compensation
	The Company records compensation expense for stock-based awards issued to employees and directors in exchange for services provided based on the estimated fair value of the awards on their grant dates and is recognized over the required service periods (generally the vesting period). For nonstatutory options, the cash flows resulting from the tax benefit due to tax deductions in excess of the compensation expense recognized for those options (excess tax benefit) are classified as financing activities within the statement of cash flows. The Company’s stock-based awards include stock option grants and restricted stock unit awards (“RSUs”).
	The following table summarizes the stock-based compensation for options and RSUs (in thousands):
			Three Months		Three Months		Six		Six
			Ended		Ended		Months		Months
			November		November		Ended		Ended
			30		24		November		November
			,		,		30		24
			2014		2013		,		,
							2014		2013
	Options		$	122,000	$	177,000	$	255,000	$	285,000
	RSUs			228,000		184,000	$	493,000	$	354,000
	Total stock-based compensation		$	350,000	$	361,000	$	748,000	$	639,000
	The following table summarizes the stock-based compensation by income statement line item:
			Three Months		Three Months		Six		Six
			Ended		Ended		Months		Months
			November		November		Ended		Ended
			30		24		November		November
			,		,		30		24
			2014		2013		,		,
							2014		2013
	Research and development		$	8,000	$	—	$	20,000	$	14,000
	Sales, general and administrative			342,000		361,000		728,000		625,000
	Total stock-based compensation		$	350,000	$	361,000	$	748,000	$	639,000
	The estimated fair value for stock options, which determines the Company’s calculation of compensation expense, is based on the Black-Scholes option pricing model. RSUs are valued at the closing market price of the Company’s common stock on the date of grant. The Company uses the straight line single option method to calculate and recognize the fair value of stock-based compensation arrangements. In addition, the Company uses historical data to estimate pre-vesting forfeitures and records stock-based compensation expense only for those awards that are expected to vest and revises those estimates in subsequent periods if the actual forfeitures differ from the prior estimates.
	As of November 30, 2014, there was $1.9 million of total unrecognized compensation expense related to unvested equity compensation awards granted under the Landec incentive stock plans. Total expense is expected to be recognized over the weighted-average period of 1.5 years for stock options and 1.4 years for RSUs
	.

Note_4_Diluted_Net_Income_Per_

Note 4 - Diluted Net Income Per Share	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Earnings Per Share [Text Block]	4	Diluted Net Income Per Share
	The following table calculates diluted net income per share (in thousands, except per share amounts):
			Three Months Ended		Three Months Ended		Six Months		Six Months
			30-Nov		November 24,		Ended		Ended
			,		2013		November 30,		November 24,
			2014				2014		2013
	Numerator:
	Net income applicable to Common Stockholders		$	3,223	$	3,451	$	5,576	$	8,203
	Denominator:
	Weighted average shares for basic net income per share			26,864		26,571		26,852		26,512
	Effect of dilutive securities:
	Stock options and restricted stock units			450		499		441		569
	Weighted average shares for diluted net income per share			27,314		27,070		27,293		27,081
	Diluted net income per share		$	0.12	$	0.13	$	0.2	$	0.3
	For the three months ended November 30, 2014 and November 24, 2013, the computation of the diluted net income per share excludes the impact of options to purchase 321,500 shares and 342,500 shares of Common Stock, respectively, as such impacts would be antidilutive for these periods.
	For the six months ended November 30, 2014 and November 24, 2013, the computation of the diluted net income per share excludes the impact of options to purchase 329,056 shares and 273,882 shares of Common Stock, respectively, as such impacts would be antidilutive for these periods.

Note_5_Income_Taxes

Note 5 - Income Taxes	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5	Income Taxes
	The provision for income taxes for the three and six months ended November 30, 2014 was $1.8 million and $3.1 million, respectively. The effective tax rate for the six months ended November 30, 2014 was 36%, compared to 35% for the first six months of fiscal year 2014.
	The effective tax rate for the six months ended November 30, 2014 was higher than the statutory federal income tax rate of 35% primarily due to several factors, including state taxes and non-deductible stock-based compensation expense; offset by the domestic manufacturing deduction and state research and development credits. The federal research and development credit statue expired as of December 31, 2013 and was not yet renewed as of November 30, 2014 and therefore not considered as of November 30, 2014.
	As of both November 30, 2014 and May 25, 2014, the Company had unrecognized tax benefits of approximately $945,000 and $1.0 million, respectively.  Included in the balance of unrecognized tax benefits as of November 30, 2014 and May 25, 2014 is approximately $759,000 and $807,000, respectively, of tax benefits that, if recognized, would result in an adjustment to the Company’s effective tax rate.
	The Company does not expect its unrecognized tax benefits to change significantly within the next twelve months.
	The Company has elected to classify interest and penalties related to uncertain tax positions as a component of its provision for income taxes.  The Company has accrued an insignificant amount of interest and penalties relating to the income tax on the unrecognized tax benefits as of November 30, 2014 and May 25, 2014.
	Due to tax attribute carryforwards, the Company is subject to examination for tax years 1997 forward for U.S. tax purposes. The Company is also subject to examination in various state jurisdictions for tax years 1998 forward, none of which were individually material.

Note_6_Inventories

Note 6 - Inventories	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Inventory Disclosure [Text Block]	6	Inventories
	Inventories are stated at the lower of cost (first-in, first-out method) or market and consisted of the following (in thousands):
			November 30,		May 25,
			2014		2014
	Finished goods		$	14,304	$	11,111
	Raw materials			12,089		10,376
	Work in progress			4,047		3,248
	Total		$	30,440	$	24,735

Note_7_Debt

Note 7 - Debt	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Debt Disclosure [Text Block]	7	Debt
	Long-term debt consists of the following (in thousands):
			November 30,			May 25,
			2014			2014
	Real estate loan agreement with General Electric Capital Corporation (“GE Capital”); due in monthly principal and interest payments of $133,060 through May 1, 2022 with interest based on a fixed rate of 4.02% per annum		$	15,659		$	16,137
	Capital equipment loan with GE Capital; due in monthly principal and interest payments of $175,356 through May 1, 2019 with interest based on a fixed rate of 4.39% per annum			8,578			9,430
	Capital equipment loan with GE Capital; due in monthly principal and interest payments of $95,120 through September 1, 2019 with interest based on a fixed rate of 3.68% per annum			6,924			—
	Capital equipment loan with GE Capital; due in monthly principal and interest payments of $55,828 through December 1, 2019 with interest based on a fixed rate of 3.74% per annum			4,124			—
	Term note with BMO Harris Bank N.A. (“BMO Harris”); due in monthly payments of $250,000 through May 23, 2016 with interest payable monthly at LIBOR plus 2% per annum			4,500			6,000
	Industrial revenue bonds (“IRBs”) issued by Lifecore; due in annual payments through 2020 with interest at a variable rate set weekly by the bond remarketing agent (0.25% and 0.28% at November 30, 2014 and May 25, 2014, respectively)			2,440			2,805
	Total			42,225			34,372
	Less current portion			(7,550	)		(6,055	)
	Long-term portion		$	34,675		$	28,317
	On July 17, 2014, Apio entered into an amendment with GE Capital, which amended the revolving line of credit dated April 23, 2012 among the parties. Under the amendment, the revolving line of credit increased from $25 million to $40 million, the interest rate was reduced from LIBOR plus 2.0% to LIBOR plus 1.75%, the term was extended to July 17, 2019 and the parties made certain other insignificant changes. The availability under the revolving line of credit is based on the combination of the eligible accounts receivable and eligible inventory (availability was $31.1 million at November 30, 2014). Apio’s revolving line of credit has an unused fee of 0.375% per annum. At November 30, 2014 and May 25, 2014, $5.0 million and zero were outstanding under Apio’s revolving line of credit.
	Also on July 17, 2014, Apio entered into a new equipment loan whereby Apio can borrow up to $25 million based on eligible equipment purchases between August 1, 2012 and August 31, 2015. Each borrowing under this new equipment loan has a five year term with a seven year amortization period. On August 28, 2014, Apio borrowed $7.1 million under the new equipment loan at a fixed rate of 3.68%. On November 24, 2014, Apio borrowed an additional $4.1 million under the new equipment loan at a fixed rate of 3.74%.
	The GE Capital real estate, equipment and line of credit agreements (collectively the “GE Debt Agreements”) are secured by liens on all of the property of Apio and its subsidiaries. The GE Debt Agreements contain customary events of default under which obligations could be accelerated or increased. The GE Debt Agreements are guaranteed by Landec and Landec has pledged its equity interest in Apio as collateral under the line of credit agreement. The GE Debt Agreements contain customary covenants, such as limitations on the ability to (1) incur indebtedness or grant liens or negative pledges on Apio’s assets; (2) make loans or other investments; (3) pay dividends, sell stock or repurchase stock or other securities; (4) sell assets; (5) engage in mergers; (6) enter into sale and leaseback transactions; and (7) make changes in Apio’s corporate structure. In addition, Apio must maintain a minimum fixed charge coverage ratio of not less than 1.10 to 1.0 if the availability under its line of credit falls below $12.0 million. Apio was in compliance with all financial covenants as of November 30, 2014 and May 25, 2014.
	During the six months ended November 30, 2014, Apio capitalized $293,000 of loan origination fees from the revolving line of credit amendment and from the new equipment loan with GE Capital. These fees are being amortized over a five year period. Unamortized loan origination fees associated with all of the GE Capital debt agreements were $1.2 million and $1.0 million at November 30, 2014 and May 25, 2014, respectively, and are included in other assets in the Consolidated Balance Sheets.
	Amortization of loan origination fees for Apio recorded to interest expense for the three months ended November 30, 2014 and November 24, 2013 were $51,000 and $47,000, respectively. Amortization of loan origination fees for Apio recorded to interest expense for the six months ended November 30, 2014 and November 24, 2013 were $97,000 and $94,000, respectively.
	On May 23, 2012, Lifecore entered into two financing agreements with BMO Harris and/or its affiliates, collectively (the “Lifecore Loan Agreements”):
		1)	A Credit and Security Agreement (the “Credit Agreement”) which includes (a) a one-year, $10.0 million asset-based working capital revolving line of credit, with an interest rate of LIBOR plus 1.85%, with availability based on the combination of Lifecore’s eligible accounts receivable and inventory balances (availability was $7.8 million at November 30, 2014) and with no unused fee (at November 30, 2014 and May 25, 2014, no amounts were outstanding under the line of credit) and (b) a $12.0 million term loan which matures in May 2016 due in monthly payments of $250,000 with interest payable monthly based on a variable interest rate of LIBOR plus 2% (the “Term Loan”).
		2)	A Reimbursement Agreement pursuant to which BMO Harris caused its affiliate Bank of Montreal to issue an irrevocable letter of credit in the amount of $3.5 million (the “Letter of Credit”) which is securing the IRB described below.
	The obligations of Lifecore under the Lifecore Loan Agreements are secured by liens on all of the property of Lifecore. The Lifecore Loan Agreements contain customary covenants, such as limitations on the ability to (1) incur
	indebtedness or grant liens or negative pledges on Lifecore’s assets; (2) make loans or other investments; (3) pay dividends or repurchase stock or other securities; (4) sell assets; (5) engage in mergers; (6) enter into sale and leaseback transactions; (7) adopt certain benefit plans; and (8) make changes in Lifecore’s corporate structure. In addition, under the Credit Agreement, Lifecore must maintain (a) a minimum fixed charge coverage ratio of 1.10 to 1.0 and a minimum quick ratio of 1.25 to 1.00, both of which must be satisfied as of the end of each fiscal quarter and (b) a minimum tangible net worth of $29,000,000, measured as of the end of each fiscal year. Lifecore was in compliance with all financial covenants as of November 30, 2014 and May 25, 2014. Unamortized loan origination fees for the Lifecore Loan Agreements were $73,000 and $98,000 at November 30, 2014 and May 25, 2014, respectively, and are included in other assets in the Consolidated Balance Sheets. Amortization of loan origination fees recorded to interest expense for both the three months ended November 30, 2014 and November 24, 2013 was $13,000. Amortization of loan origination fees recorded to interest expense for both the six months ended November 30, 2014 and November 24, 2013 was $26,000.
	The market value of the Company’s debt approximates its recorded value as the interest rate on each debt instrument approximates current market rates.
	The Term Loan was used to repay Lifecore’s former credit facility with Wells Fargo Bank, N.A. (“Wells Fargo”). The Letter of Credit (which replaces a letter of credit previously provided by Wells Fargo) provides liquidity
	and credit support for the IRBs.
	On August 19, 2004, Lifecore issued variable rate industrial revenue bonds (“IRBs”) which were assumed by Landec in the acquisition of Lifecore. The IRBs are collateralized by a bank letter of credit which is secured by a first mortgage on the Company’s facility in Chaska, Minnesota.
	In addition, the Company pays an
	annual remarketing fee equal to 0.125% and an annual letter of credit fee of 0.75% on the outstanding principal balance.
	The maturities on the IRBs are held in a sinking fund account, recorded in other assets in the accompanying Consolidated Balance Sheets, and are paid out each year on September 1st.

Note_8_Derivative_Financial_In

Note 8 - Derivative Financial Instruments	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	8	Derivative Financial Instruments
	.
	In May 2010, the Company entered into a five-year interest rate swap agreement under its prior credit agreement with Wells Fargo, which expires on April 30, 2015. The interest rate swap was originally designated as a cash flow hedge of future interest payments of LIBOR and had a notional amount of $20 million. As a result of the interest rate swap transaction, the Company fixed for a five-year period the interest rate at 4.24% subject to market based interest rate risk on $20 million of borrowings under the credit agreement with Wells Fargo. The Company’s obligations under the interest rate swap transaction as to the scheduled payments were guaranteed and secured on the same basis as its obligations under the credit agreement with Wells Fargo at the time the agreement was consummated. Upon entering into the new Term Loan with BMO Harris, the Company used the proceeds from that loan to pay off the Wells Fargo credit facility. The swap with Wells Fargo was not terminated upon the extinguishment of the debt with Wells Fargo. The fair value of the swap arrangement as of November 30, 2014 and May 25, 2014 was $9,000 and $44,000, respectively, and is included in other accrued liabilities in the accompanying Consolidated Balance Sheets.

Note_9_Related_Party

Note 9 - Related Party	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	9	Related Party
	The Company sells products to and earns license fees from Windset. During the three months ended November 30, 2014 and November 24, 2013, the Company recognized revenues of $161,000 and $16,000, respectively. During the six months ended November 30, 2014 and November 24, 2013, the Company recognized revenues of $195,000 and $21,000, respectively. These amounts have been included in product sales in the accompanying Consolidated Statements of Comprehensive Income, from the sale of products to and license fees from Windset. The related receivable balances of $162,000 and $304,000 are included in accounts receivable, related party, in the accompanying Consolidated Balance Sheets as of November 30, 2014 and May 25, 2014, respectively.
	Additionally, unrelated to the revenue transactions above, the Company purchases produce from Windset for sale to third parties. During the three months ended November 30, 2014 and November 24, 2013, the Company recognized cost of product sales of $297,000 and $431,000, respectively. During the six months ended November 30, 2014 and November 24, 2013, the Company recognized cost of product sales of $708,000 and $812,000, respectively. These amounts have been included in cost of product sales in the accompanying Consolidated Statements of Comprehensive Income, from the sale of products purchased from Windset. The related accounts payable of $332,000 and $134,000 are included in accounts payable, related party in the accompanying Consolidated Balance Sheets as of November 30, 2014 and May 25, 2014, respectively.
	All related party transactions are monitored quarterly by the Company and approved by the Audit Committee of the Board of Directors.

Note_10_Stockholders_Equity

Note 10 - Stockholders' Equity	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10	Stockholders’ Equity
	During the three months ended November 30, 2014, the Company did not grant any equity awards. During the six months ended November 30, 2014, the Company granted options to purchase 30,000 shares of common stock and awarded 43,752 restricted stock units
	.
	As of November 30, 2014 the Company has reserved 3.1 million shares of Common Stock for future issuance under its current and former equity plans.
	On July 14, 2010, the Company announced that the Board of Directors of the Company had approved the establishment of a stock repurchase plan authorizing the repurchase of up to $10 million of the Company’s Common Stock. The Company may repurchase its common stock from time to time in open market purchases or in privately negotiated transactions. The timing and actual number of shares repurchased is at the discretion of management of the Company and will depend on a variety of factors, including stock price, corporate and regulatory requirements, market conditions, the relative attractiveness of other capital deployment opportunities and other corporate priorities. The stock repurchase program does not obligate Landec to acquire any amount of its common stock and the program may be modified, suspended or terminated at any time at the Company's discretion without prior notice. During the three and six months ended November 30, 2014, the Company did not purchase any shares on the open market.
	- 17-
	Consolidated Statements of Changes in Stockholders
	’
	Equity
	(in thousands, except share amounts):
	Common Stock Shares
	Balance at May 25, 2014			26,815,253
	Stock options exercised, net of shares tendered			31,235
	Vested restricted stock units, net of shares tendered			29,496
	Balance at November 30, 2014			26,875,984
	Common Stock
	Balance at May 25, 2014		$	27
	Stock options exercised, net of shares tendered			—
	Vested restricted stock units, net of shares tendered			—
	Balance at November 30, 2014		$	27
	Additional Paid-in Capital
	Balance at May 25, 2014		$	131,488
	Stock options exercised, net of shares tendered			100
	Vested restricted stock units, net of shares tendered			—
	Taxes paid by Company for stock swaps and restricted stock units			(12	)
	Stock-based compensation expense			748
	Tax benefit from stock based compensation			36
	Balance at November 30, 2014		$	132,360
	Retained Earnings
	Balance at May 25, 2014		$	71,554
	Net income			5,576
	Balance at November 30, 2014		$	77,130
	Non
	-
	controlling Interest
	Balance at May 25, 2014		$	1,692
	Non-controlling interest in net income			95
	Distributions to non-controlling interest			(196	)
	Balance at November 30, 2014		$	1,591

Note_11_Business_Segment_Repor

Note 11 - Business Segment Reporting	6 Months Ended
	Nov. 30, 2014
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1	Business Segment Reporting
	1
	.
	The Company manages its business operations through three strategic business units. Based upon the information reported to the chief operating decision maker, who is the Chief Executive Officer, the Company has the following reportable segments
	: the Food Products Technology segment, the Food Export segment and the Hyaluronan-based Biomaterials segment.
	The Food Products Technology segment markets and packs specialty packaged whole and fresh-cut fruit and vegetables, the majority of which incorporate the BreatheWay specialty packaging for the retail grocery, club store and food services industry. In addition, the Food Products Technology segment sells BreatheWay packaging to partners for non-vegetable products. The Food Export segment consists of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia and domestically. The HA-based Biomaterials segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, for medical use primarily in the Ophthalmic, Orthopedic and Veterinary markets. Corporate licenses Landec’s patented Intellicoat seed coatings to the farming industry and licenses the Company’s Intelimer polymers for personal care products and other industrial products. The Corporate segment also includes general and administrative expenses, non-Food Products Technology and non HA-based Biomaterials interest income and income tax expenses. All of the assets of the Company are located within the United States of America.
	The Company’s international sales were as follows (in millions):
			Three Months Ended				Six Months Ended
			November 30,		November 24,		November 30,			November 24,
			2014		2013		2014			2013
	Canada		$	17.5	$	10.2	$	35.2		$	19.6
	Taiwan		$	9.4	$	12.6	$	25.6		$	24.6
	China		$	2.9	$	3.7	$	7.3		$	5.3
	Indonesia		$	4.9	$	2.4	$	6.5		$	4.9
	Japan		$	2.3	$	2.1	$	5.1		$	5.3
	Belgium		$	—	$	0.8	$	—		$	2
	All Other Countries		$	4.6	$	4.9	$	8.3		$	10.2
	Operations by segment consisted of the following (in thousands):
	Three Months Ended Nov. 30, 2014		Food Products Technology		Food Export		HA-based Biomaterials			Corporate			TOTAL
	Net sales		$	102,079	$	22,106	$	8,318		$	162		$	132,665
	International sales		$	17,760	$	22,106	$	1,734		$	—		$	41,600
	Gross profit		$	11,151	$	1,550	$	2,804		$	161		$	15,666
	Net income (loss)		$	3,644	$	582	$	(12	)	$	(991	)	$	3,223
	Depreciation and amortization		$	1,237	$	1	$	561		$	31		$	1,830
	Dividend income		$	321	$	—	$	—		$	—		$	321
	Interest income		$	15	$	—	$	67		$	9		$	91
	Interest expense		$	425	$	—	$	47		$	—		$	472
	Income tax expense		$	440	$	95	$	(2	)	$	1,252		$	1,785
	Three Months Ended Nov. 24, 2013
	Net sales		$	88,090	$	23,031	$	8,777		$	128		$	120,026
	International sales		$	10,345	$	22,940	$	3,366		$	—		$	36,651
	Gross profit		$	8,220	$	1,820	$	3,625		$	69		$	13,734
	Net income (loss)		$	2,005	$	727	$	611		$	108		$	3,451
	Depreciation and amortization		$	1,304	$	1	$	604		$	36		$	1,945
	Dividend income		$	281	$	—	$	—		$	—		$	281
	Interest income		$	2	$	—	$	44		$	—		$	46
	Interest expense		$	356	$	—	$	80		$	—		$	436
	Income tax expense		$	1,461	$	205	$	172		$	36		$	1,874
	Six Months Ended Nov. 30, 2014
	Net sales		$	202,185	$	48,703	$	15,129		$	262		$	266,279
	International sales		$	35,911	$	48,693	$	3,368		$	—		$	87,972
	Gross profit		$	23,005	$	2,736	$	3,852		$	261		$	29,854
	Net income (loss)		$	7,290	$	853	$	(1,554	)	$	(1,013	)	$	5,576
	Depreciation and amortization		$	2,247	$	2	$	1,032		$	62		$	3,343
	Dividend income		$	602	$	—	$	—		$	—		$	602
	Interest income		$	26	$	—	$	138		$	20		$	184
	Interest expense		$	763	$	—	$	92		$	—		$	855
	Income tax expense		$	1,310	$	139	$	(253	)	$	1,890		$	3,086
	Six Months Ended Nov. 24, 2013
	Net sales		$	167,526	$	44,430	$	17,363		$	186		$	229,505
	International sales		$	19,823	$	44,329	$	7,743		$	—		$	71,895
	Gross profit		$	17,101	$	3,025	$	6,013		$	127		$	26,266
	Net income (loss)		$	9,271	$	1,003	$	235		$	(2,306	)	$	8,203
	Depreciation and amortization		$	2,526	$	2	$	1,188		$	71		$	3,787
	Dividend income		$	563	$	—	$	—		$	—		$	563
	Interest income		$	5	$	—	$	100		$	—		$	105
	Interest expense		$	732	$	—	$	135		$	—		$	867
	Income tax expense		$	1,966	$	283	$	66		$	2,034		$	4,349
	During the six months ended November 30, 2014 and November 24, 2013, sales to the Company’s top five customers accounted for 44% and 43%, respectively, of revenues. The Company’s top two customers, Costco Wholesale Corporation and Wal-Mart Stores, Inc., from the Food Products Technology segment accounted for 20% and 11% of revenues, respectively, for the six months ended November 30, 2014 and 20% and 11% of revenues, respectively, for the six months ended November 24, 2013. The Company expects that, for the foreseeable future, a limited number of customers may continue to account for a significant portion of its net revenues.

Significant_Accounting_Policie

Significant Accounting Policies (Policies)	6 Months Ended
	Nov. 30, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
	The accompanying unaudited consolidated financial statements of Landec have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring accruals) have been made which are necessary to present fairly the financial position at November 30, 2014, and the results of operations and cash flows for all periods presented. Although Landec believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements and related footnotes prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission. The accompanying financial data should be reviewed in conjunction with the audited financial statements and accompanying notes included in Landec's Annual Report on Form 10-K for the fiscal year ended May 25, 2014.
	The results of operations for the six months ended November 30, 2014 are not necessarily indicative of the results that may be expected for an entire fiscal year because there is some seasonality in Apio’s food business, particularly, Apio’s Food Export business and the order patterns of Lifecore’s customers which may lead to significant fluctuations in Landec’s quarterly results of operations. In addition, the first quarter of fiscal year 2015 was a 14-week quarter which occurs once every six years compared to the standard 13-week quarter.
Consolidation, Policy [Policy Text Block]	Basis of Consolidation
	The consolidated financial statements are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States and include the accounts
	of Landec Corporation and its subsidiaries, Apio and Lifecore. All material inter-company transactions and balances have been eliminated.
	Arrangements that are not controlled through voting or similar rights are reviewed under the guidance for variable interest entities (“VIEs”). A company is required to consolidate the assets, liabilities and operations of a VIE if it is determined to be the primary beneficiary of the VIE.
	An entity is a VIE and subject to consolidation, if by design: a) the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support provided by any parties, including equity holders or b) as a group the holders of the equity investment at risk lack any one of the following three characteristics: (i) the power, through voting rights or similar rights to direct the activities of an entity that most significantly impact the entity’s economic performance, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity. The Company reviewed the consolidation guidance and concluded that its partnership interest in Apio Cooling and its equity investments in non-public companies are not VIEs.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; sales returns and allowances; self insurance liabilities; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived assets; the valuation of intangible assets and inventory; the valuation of investments; and the valuation and recognition of stock-based compensation.
	These estimates involve the consideration of complex factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and is subject to change from period to period. The actual results may differ from management’s estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	The Company records all highly liquid securities with three months or less from date of purchase to maturity as cash equivalents. Cash equivalents consisted of money market funds of $1.5 million at both November 30, 2014 and May 25, 2014. The market value of cash equivalents approximates their historical cost given their short-term nature.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments
	The Company’s financial instruments are primarily composed of marketable securities, commercial-term trade payables, grower advances, notes receivable and debt instruments. For short-term instruments, the historical carrying amount approximates the fair value of the instrument. The fair value of long-term debt and lines of credit approximates their carrying value. Fair values for long-term financial instruments not readily marketable are estimated based upon discounted future cash flows at prevailing market interest rates. Based on these assumptions, management believes the fair values of the Company’s financial instruments are not materially different from their recorded amounts as of November 30, 2014 and May 25, 2014.
Investment In Non Public Companies [Policy Text Block]	Investments in Non-Public Companies
	The Company’s investment in Aesthetic Sciences Corporation (“Aesthetic Sciences”), which is reported as an investment in non-public company, non-fair value, in the accompanying Consolidated Balance Sheets, is carried at cost and adjusted for impairment losses. Since there is no readily available market value information, the Company periodically reviews this investment to determine if any other than temporary declines in value have occurred based on the financial stability and viability of Aesthetic Sciences.
	On February 15, 2011, Apio purchased 150,000 senior preferred shares for $15 million and 201 common shares for $201 that were issued by Windset Holdings 2010 Ltd., a Canadian corporation (“Windset”). On July 15, 2014, Apio increased its investment in Windset by purchasing an additional 68 shares of common stock and 51,211 shares of junior preferred stock of Windset for $11.0 million. On October 29, 2014, Apio purchased an additional 70,000 senior preferred shares of Windset for $7.0 million. These investments are reported as an investment in non-public company, fair value, in the accompanying Consolidated Balance Sheets as of November 30, 2014 and May 25, 2014. The Company has elected to account for its investment in Windset under the fair value option (see Note 2).
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible Assets
	The Company’s intangible assets are comprised of customer relationships with a finite estimated useful life of twelve to thirteen years and trademarks, trade names and goodwill with indefinite lives.
	Finite-lived intangible assets are reviewed for possible impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an asset (or asset group) may not be recoverable.  Indefinite lived intangible assets are reviewed for impairment at least annually. For non-goodwill indefinite-lived intangible assets, the Company performs a qualitative analysis in accordance with ASC 350-30-35. For goodwill, the Company has historically performed a quantitative analysis in accordance with ASC 350-20-35.
Self Insurance Reserve [Policy Text Block]	Partial Self-Insurance on Employee Health Plan
	The Company provides health insurance benefits to eligible employees under a self-insured plan whereby the Company pays actual medical claims subject to certain stop loss limits. The Company records self-insurance liabilities based on actual claims filed and an estimate of those claims incurred but not reported. Any projection of losses concerning the Company's liability is subject to a high degree of variability. Among the causes of this variability are unpredictable external factors such as inflation rates, changes in severity, benefit level changes, medical costs, and claims settlement patterns. This self-insurance liability is included in accrued liabilities and represents management's best estimate of the amounts that have not been paid as of November 30, 2014 and May 25, 2014. It is reasonably possible that the expense the Company ultimately incurs could differ and adjustments to future reserves may be necessary.
Compensation Related Costs, Policy [Policy Text Block]	Long-Term Incentive Plan
	On July 25, 2013, the Landec Long-Term Incentive Plan (“LTIP”) was established which allows certain executives to earn a performance-based bonus that is based upon a cumulative operating income target for fiscal years 2014, 2015, and 2016. The LTIP was designed to align the interests of management with the long-term financial success of the Company. If the three-year cumulative operating income target had been met, approximately $2.0 million in bonuses would have been paid. Through fiscal year 2014, the Company was recording the estimated plan bonus on a straight-line basis over the 36-month LTIP period. As of August 31, 2014, the Company determined it was unlikely the three-year cumulative operating income target would be attained and therefore all LTIP bonus accruals were reversed at that date. The reversal resulted in a $677,000 reduction in selling, general, and administrative expenses during the six months ended November 30, 2014 in the accompanying Consolidated Statements of Comprehensive Income. The long-term incentive bonuses accrued under this plan of zero and $677,000 are included in other non-current liabilities in the accompanying Consolidated Balance Sheets as of November 30, 2014 and May 25, 2014, respectively.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements
	The Company uses fair value measurement accounting for financial assets and liabilities and for financial instruments and certain other items measured at fair value. The Company has elected the fair value option for its investment in a non-public company (see Note 2). The Company has not elected the fair value option for any of its other eligible financial assets or liabilities.
	The accounting guidance established a three-tier hierarchy for fair value measurements, which prioritizes the inputs used in measuring fair value as follows:
	Level 1 – observable inputs such as quoted prices for identical instruments in active markets.
	Level 2 – inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.
	Level 3 – unobservable inputs in which there is little or no market data, which would require the Company to develop its own assumptions.
	As of November 30, 2014, the Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis, including an interest rate swap and a minority interest investment in Windset.
	The fair value of the Company’s interest rate swap is determined based on model inputs that can be observed in a liquid market, including yield curves, and is categorized as a Level 2 measurement.
	The Company has elected the fair value option of accounting for its investment in Windset. The calculation of fair value utilizes significant unobservable inputs, including projected cash flows, growth rates and discount rates. As a result, the Company’s investment in Windset is considered to be a Level 3 measurement investment. The change in the fair value of the Company’s investment in Windset for the six months ended November 30, 2014 was due to the Company’s 26.9% minority interest in the change in the fair market value of Windset during the period. In determining the fair value of the investment in Windset, the Company utilizes the following significant unobservable inputs in the discounted cash flow models:
		At November 30, 2014			At May 25, 2014
	Revenue growth rates		4%			4%
	Expense growth rates		4%			4%
	Income tax rates		15%			15%
	Discount rates		16% to 22%			16% to 22%
	The revenue growth, expense growth and income tax rate assumptions, consider the Company's best estimate of the trends in those items over the discount period.   The discount rate assumption takes into account the risk-free rate of return, the market equity risk premium and the company’s specific risk premium and then applies an additional discount for lack of liquidity of the underlying securities.    The discounted cash flow valuation model used by the Company has the following sensitivity to changes in inputs and assumptions (in thousands):
	Impact on value of Windset investment as of November 30, 2014
	10% increase in revenue growth rates	$	4,900
	10% increase in expense growth rates	$	(4,100	)
	10% increase in income tax rates	$	—
	10% increase in discount rates	$	(700	)
	Imprecision in estimating unobservable market inputs can affect the amount of gain or loss recorded for a particular position. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
	The following table summarizes the fair value of the Company’s assets and liabilities that are measured at fair value on a recurring basis, as of November 30, 2014 and May 25, 2014 (in thousands):
		Fair Value at November 30, 2014							Fair Value at May 25, 2014
		Level 1			Level 2		Level 3		Level 1		Level 2		Level 3
	Assets:
	Investment in private company		-			-		59,000		-		-		39,600
	Total	$	-		$	-	$	59,000	$	-	$	-	$	39,600
	Liabilities:
	Interest rate swap		-			9		-		-		44		-
	Total	$	-		$	9	$	-	$	-	$	44	$	-
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	Revenue from product sales is recognized when there is persuasive evidence that an arrangement exists, title has transferred, the price is fixed and determinable, and collectability is reasonably assured. Allowances are established for estimated uncollectible amounts, product returns, and discounts based on specific identification and historical losses.
	Apio’s Food Products Technology revenues generally consist of revenues generated from the sale of specialty packaged fresh-cut and whole value-added processed vegetable products that are generally washed and packaged in the Company’s proprietary packaging and sold under Apio’s Eat Smart and GreenLine brands and various private labels. Revenue is generally recognized upon shipment of these products to customers. The Company takes title to all produce it trades and/or packages, and therefore, records revenues and cost of sales at gross amounts in the Consolidated Statements of Comprehensive Income
	In addition, Food Products Technology value-added revenues include the revenues generated from Apio Cooling, LP, a vegetable cooling operation in which Apio is the general partner with a 60% ownership position and from the sale of BreatheWay packaging to license partners. Revenue is recognized on the vegetable cooling operations as cooling and storage services are provided to the Company’s customers. Sales of BreatheWay packaging are recognized when shipped to the customer.
	Apio’s Food Export revenues consist of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia by Cal-Ex. As most Cal-Ex customers are in countries outside of the U.S., title transfers and revenue is generally recognized upon arrival of the shipment in the foreign port. Apio records revenue equal to the sale price to third parties because it takes title to the product while in transit.
	The HA-based Biomaterials business principally generates revenue through the sale of products containing HA. Lifecore primarily sells products to customers in three medical areas: (1) Ophthalmic, which represented approximately 60% of Lifecore’s revenues in fiscal year 2014, (2) Orthopedic, which represented approximately 20% of Lifecore’s revenues in fiscal year 2014 and (3) Veterinary/Other. The vast majority of revenues from the Company’s HA-based Biomaterials business are recognized upon shipment.
	A small amount of revenues from the HA-based Biomaterials business is related to contract research and development (R&D) services and multi-element arrangement services with customers where the Company provides products and/or services in a bundled arrangement.
	Contract R&D revenue is recorded as earned, based on the performance requirements of the contract. Non-refundable contract fees for which no further performance obligations exist, and there is no continuing involvement by the Company, are recognized on the earlier of when the payment is received or collection is assured.
	For sales arrangements that contain multiple elements, the Company splits the arrangement into separate units of accounting if the individually delivered elements have value to the customer on a standalone basis. The Company also evaluates whether multiple transactions with the same customer or related party should be considered part of a multiple element arrangement, whereby the Company assesses, among other factors, whether the contracts or agreements are negotiated or executed within a short time frame of each other or if there are indicators that the contracts are negotiated in contemplation of each other. The Company then allocates revenue to each element based on a selling price hierarchy. The relative selling price for a deliverable is based on its vendor-specific objective evidence (VSOE), if available, third-party evidence (TPE), if VSOE is not available, or estimated selling price, if neither VSOE nor TPE is available. The Company then recognizes revenue on each deliverable in accordance with its policies for product and service revenue recognition. The Company is not typically able to determine VSOE or TPE, and therefore, uses the estimated selling price to allocate revenue between the elements of an arrangement.
	The Company limits the amount of revenue recognition for delivered elements to the amount that is not contingent on the future delivery of products or services or future performance obligations or subject to customer-specific cancellation rights. The Company evaluates each deliverable in an arrangement to determine whether it represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has stand-alone value, and for an arrangement that includes a general right of return relative to the delivered products or services, delivery or performance of the undelivered product or service is considered probable and is substantially controlled by the Company. The Company considers a deliverable to have stand-alone value if the product or service is sold separately by the Company or another vendor or could be resold by the customer. Further, the revenue arrangements generally do not include a general right of return relative to delivered products. Where the aforementioned criteria for a separate unit of accounting are not met, the deliverable is combined with the undelivered element(s) and treated as a single unit of accounting for the purposes of allocation of the arrangement consideration and revenue recognition. The Company allocates the total arrangement consideration to each separable element of an arrangement based upon the relative selling price of each element. Allocation of the consideration is determined at arrangement inception on the basis of each unit’s relative selling price. In instances where the Company has not established fair value for any undelivered element, revenue for all elements is deferred until delivery of the final element is completed and all recognition criteria are met.
	Licensing revenue is recognized in accordance with prevailing accounting guidance. Initial license fees are deferred and amortized to revenue over the period of the agreement when a contract exists, the fee is fixed and determinable, and collectability is reasonably assured. Noncancellable, nonrefundable license fees are recognized over the period of the agreement, including those governing research and development activities and any related supply agreement entered into concurrently with the license when the risk associated with commercialization of a product is non-substantive at the outset of the arrangement.
	From time to time, the Company offers customers sales incentives, which include volume rebates and discounts. These amounts are estimated on a quarterly basis and recorded as a reduction of revenue.
	A summary of revenues by type of revenue arrangement as described above is as follows (in thousands):
		Three months			Three months		Six months		Six months
		ended			ended		ended		ended
		30-Nov			24-Nov		30-Nov		24-Nov
		, 2014			, 201		, 2014		, 201
					3				3
	Recorded upon shipment	$	109,764		$	95,002	$	216,004	$	182,412
	Recorded upon acceptance in foreign port		22,106			22,940		48,693		44,329
	Revenue from license fees, R&D contracts and royalties/profit sharing		423			143		635		201
	Revenue from multiple element arrangements		372			1,941		947		2,563
	Total	$	132,665		$	120,026	$	266,279	$	229,505
New Accounting Pronouncements, Policy [Policy Text Block]	New
	Accounting Pronouncements
	Revenue Recognition
	In May 2014, the FASB issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"), which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a cohesive set of disclosure requirements intended to provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a company’s contracts with customers. ASU 2014-09 will be effective beginning the first quarter of the Company's fiscal year 2018 and early application is not permitted. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. Management is currently evaluating the effect ASU 2014-09 will have on the Company's Consolidated Financial Statements and disclosures.

Note_1_Organization_Basis_of_P1

Note 1 - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Nov. 30, 2014
Notes Tables
Schedule Of Effect Of Significant Unobservable Inputs For Investment [TableText Block]		At November 30, 2014			At May 25, 2014
	Revenue growth rates		4%			4%
	Expense growth rates		4%			4%
	Income tax rates		15%			15%
	Discount rates		16% to 22%			16% to 22%
Schedule of Sensitivity Analysis of Fair Value, Transferor's Interests in Transferred Financial Assets [Table Text Block]	Impact on value of Windset investment as of November 30, 2014
	10% increase in revenue growth rates	$	4,900
	10% increase in expense growth rates	$	(4,100	)
	10% increase in income tax rates	$	—
	10% increase in discount rates	$	(700	)
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]		Fair Value at November 30, 2014							Fair Value at May 25, 2014
		Level 1			Level 2		Level 3		Level 1		Level 2		Level 3
	Assets:
	Investment in private company		-			-		59,000		-		-		39,600
	Total	$	-		$	-	$	59,000	$	-	$	-	$	39,600
	Liabilities:
	Interest rate swap		-			9		-		-		44		-
	Total	$	-		$	9	$	-	$	-	$	44	$	-
Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]		Three months			Three months		Six months		Six months
		ended			ended		ended		ended
		30-Nov			24-Nov		30-Nov		24-Nov
		, 2014			, 201		, 2014		, 201
					3				3
	Recorded upon shipment	$	109,764		$	95,002	$	216,004	$	182,412
	Recorded upon acceptance in foreign port		22,106			22,940		48,693		44,329
	Revenue from license fees, R&D contracts and royalties/profit sharing		423			143		635		201
	Revenue from multiple element arrangements		372			1,941		947		2,563
	Total	$	132,665		$	120,026	$	266,279	$	229,505

Note_3_Stockbased_Compensation1

Note 3 - Stock-based Compensation (Tables)	6 Months Ended
	Nov. 30, 2014
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]		Three Months		Three Months		Six		Six
		Ended		Ended		Months		Months
		November		November		Ended		Ended
		30		24		November		November
		,		,		30		24
		2014		2013		,		,
						2014		2013
	Options	$	122,000	$	177,000	$	255,000	$	285,000
	RSUs		228,000		184,000	$	493,000	$	354,000
	Total stock-based compensation	$	350,000	$	361,000	$	748,000	$	639,000
		Three Months		Three Months		Six		Six
		Ended		Ended		Months		Months
		November		November		Ended		Ended
		30		24		November		November
		,		,		30		24
		2014		2013		,		,
						2014		2013
	Research and development	$	8,000	$	—	$	20,000	$	14,000
	Sales, general and administrative		342,000		361,000		728,000		625,000
	Total stock-based compensation	$	350,000	$	361,000	$	748,000	$	639,000

Note_4_Diluted_Net_Income_Per_1

Note 4 - Diluted Net Income Per Share (Tables)	6 Months Ended
	Nov. 30, 2014
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		Three Months Ended		Three Months Ended		Six Months		Six Months
		30-Nov		November 24,		Ended		Ended
		,		2013		November 30,		November 24,
		2014				2014		2013
	Numerator:
	Net income applicable to Common Stockholders	$	3,223	$	3,451	$	5,576	$	8,203
	Denominator:
	Weighted average shares for basic net income per share		26,864		26,571		26,852		26,512
	Effect of dilutive securities:
	Stock options and restricted stock units		450		499		441		569
	Weighted average shares for diluted net income per share		27,314		27,070		27,293		27,081
	Diluted net income per share	$	0.12	$	0.13	$	0.2	$	0.3

Note_6_Inventories_Tables

Note 6 - Inventories (Tables)	6 Months Ended
	Nov. 30, 2014
Notes Tables
Schedule of Inventory, Current [Table Text Block]		November 30,		May 25,
		2014		2014
	Finished goods	$	14,304	$	11,111
	Raw materials		12,089		10,376
	Work in progress		4,047		3,248
	Total	$	30,440	$	24,735

Note_7_Debt_Tables

Note 7 - Debt (Tables)	6 Months Ended
	Nov. 30, 2014
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]		November 30,			May 25,
		2014			2014
	Real estate loan agreement with General Electric Capital Corporation (“GE Capital”); due in monthly principal and interest payments of $133,060 through May 1, 2022 with interest based on a fixed rate of 4.02% per annum	$	15,659		$	16,137
	Capital equipment loan with GE Capital; due in monthly principal and interest payments of $175,356 through May 1, 2019 with interest based on a fixed rate of 4.39% per annum		8,578			9,430
	Capital equipment loan with GE Capital; due in monthly principal and interest payments of $95,120 through September 1, 2019 with interest based on a fixed rate of 3.68% per annum		6,924			—
	Capital equipment loan with GE Capital; due in monthly principal and interest payments of $55,828 through December 1, 2019 with interest based on a fixed rate of 3.74% per annum		4,124			—
	Term note with BMO Harris Bank N.A. (“BMO Harris”); due in monthly payments of $250,000 through May 23, 2016 with interest payable monthly at LIBOR plus 2% per annum		4,500			6,000
	Industrial revenue bonds (“IRBs”) issued by Lifecore; due in annual payments through 2020 with interest at a variable rate set weekly by the bond remarketing agent (0.25% and 0.28% at November 30, 2014 and May 25, 2014, respectively)		2,440			2,805
	Total		42,225			34,372
	Less current portion		(7,550	)		(6,055	)
	Long-term portion	$	34,675		$	28,317

Note_10_Stockholders_Equity_Ta

Note 10 - Stockholders' Equity (Tables)	6 Months Ended
	Nov. 30, 2014
Notes Tables
Schedule of Stockholders Equity [Table Text Block]	Common Stock Shares
	Balance at May 25, 2014		26,815,253
	Stock options exercised, net of shares tendered		31,235
	Vested restricted stock units, net of shares tendered		29,496
	Balance at November 30, 2014		26,875,984
	Common Stock
	Balance at May 25, 2014	$	27
	Stock options exercised, net of shares tendered		—
	Vested restricted stock units, net of shares tendered		—
	Balance at November 30, 2014	$	27
	Additional Paid-in Capital
	Balance at May 25, 2014	$	131,488
	Stock options exercised, net of shares tendered		100
	Vested restricted stock units, net of shares tendered		—
	Taxes paid by Company for stock swaps and restricted stock units		(12	)
	Stock-based compensation expense		748
	Tax benefit from stock based compensation		36
	Balance at November 30, 2014	$	132,360
	Retained Earnings
	Balance at May 25, 2014	$	71,554
	Net income		5,576
	Balance at November 30, 2014	$	77,130
	Non
	-
	controlling Interest
	Balance at May 25, 2014	$	1,692
	Non-controlling interest in net income		95
	Distributions to non-controlling interest		(196	)
	Balance at November 30, 2014	$	1,591

Note_11_Business_Segment_Repor1

Note 11 - Business Segment Reporting (Tables)	6 Months Ended
	Nov. 30, 2014
Notes Tables
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]		Three Months Ended				Six Months Ended
		November 30,		November 24,		November 30,			November 24,
		2014		2013		2014			2013
	Canada	$	17.5	$	10.2	$	35.2		$	19.6
	Taiwan	$	9.4	$	12.6	$	25.6		$	24.6
	China	$	2.9	$	3.7	$	7.3		$	5.3
	Indonesia	$	4.9	$	2.4	$	6.5		$	4.9
	Japan	$	2.3	$	2.1	$	5.1		$	5.3
	Belgium	$	—	$	0.8	$	—		$	2
	All Other Countries	$	4.6	$	4.9	$	8.3		$	10.2
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended Nov. 30, 2014	Food Products Technology		Food Export		HA-based Biomaterials			Corporate			TOTAL
	Net sales	$	102,079	$	22,106	$	8,318		$	162		$	132,665
	International sales	$	17,760	$	22,106	$	1,734		$	—		$	41,600
	Gross profit	$	11,151	$	1,550	$	2,804		$	161		$	15,666
	Net income (loss)	$	3,644	$	582	$	(12	)	$	(991	)	$	3,223
	Depreciation and amortization	$	1,237	$	1	$	561		$	31		$	1,830
	Dividend income	$	321	$	—	$	—		$	—		$	321
	Interest income	$	15	$	—	$	67		$	9		$	91
	Interest expense	$	425	$	—	$	47		$	—		$	472
	Income tax expense	$	440	$	95	$	(2	)	$	1,252		$	1,785
	Three Months Ended Nov. 24, 2013
	Net sales	$	88,090	$	23,031	$	8,777		$	128		$	120,026
	International sales	$	10,345	$	22,940	$	3,366		$	—		$	36,651
	Gross profit	$	8,220	$	1,820	$	3,625		$	69		$	13,734
	Net income (loss)	$	2,005	$	727	$	611		$	108		$	3,451
	Depreciation and amortization	$	1,304	$	1	$	604		$	36		$	1,945
	Dividend income	$	281	$	—	$	—		$	—		$	281
	Interest income	$	2	$	—	$	44		$	—		$	46
	Interest expense	$	356	$	—	$	80		$	—		$	436
	Income tax expense	$	1,461	$	205	$	172		$	36		$	1,874
	Six Months Ended Nov. 30, 2014
	Net sales	$	202,185	$	48,703	$	15,129		$	262		$	266,279
	International sales	$	35,911	$	48,693	$	3,368		$	—		$	87,972
	Gross profit	$	23,005	$	2,736	$	3,852		$	261		$	29,854
	Net income (loss)	$	7,290	$	853	$	(1,554	)	$	(1,013	)	$	5,576
	Depreciation and amortization	$	2,247	$	2	$	1,032		$	62		$	3,343
	Dividend income	$	602	$	—	$	—		$	—		$	602
	Interest income	$	26	$	—	$	138		$	20		$	184
	Interest expense	$	763	$	—	$	92		$	—		$	855
	Income tax expense	$	1,310	$	139	$	(253	)	$	1,890		$	3,086
	Six Months Ended Nov. 24, 2013
	Net sales	$	167,526	$	44,430	$	17,363		$	186		$	229,505
	International sales	$	19,823	$	44,329	$	7,743		$	—		$	71,895
	Gross profit	$	17,101	$	3,025	$	6,013		$	127		$	26,266
	Net income (loss)	$	9,271	$	1,003	$	235		$	(2,306	)	$	8,203
	Depreciation and amortization	$	2,526	$	2	$	1,188		$	71		$	3,787
	Dividend income	$	563	$	—	$	—		$	—		$	563
	Interest income	$	5	$	—	$	100		$	—		$	105
	Interest expense	$	732	$	—	$	135		$	—		$	867
	Income tax expense	$	1,966	$	283	$	66		$	2,034		$	4,349

Note_1_Organization_Basis_of_P2

Note 1 - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) (USD $)	6 Months Ended	36 Months Ended	0 Months Ended		1 Months Ended	12 Months Ended
	Nov. 30, 2014	29-May-16	Jul. 15, 2014	Feb. 15, 2011	Oct. 29, 2014	25-May-14
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Payments to Acquire Investments	$18,000,000
Number of Proprietary Platforms	2
HA Based Biomaterials [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Product Segments	3
Bonus Under Long-term Incentive Plan [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued Bonuses	0					677,000
Bonus Under Long-term Incentive Plan [Member] | Scenario, Forecast [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Officers' Compensation		2,000,000
Officers' Compensation		-2,000,000
Selling, General and Administrative Expenses [Member] | Bonus Under Long-term Incentive Plan [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Officers' Compensation	-677,000
Officers' Compensation	677,000
Customer Relationships [Member] | Maximum [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finite-Lived Intangible Asset, Useful Life	13 years
Customer Relationships [Member] | Minimum [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finite-Lived Intangible Asset, Useful Life	12 years
Cash and Cash Equivalents [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Money Market Funds, at Carrying Value	1,500,000					1,500,000
Apio Cooling, LP [Member] | Apio [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investment Ownership Percentage	60.00%
Windset [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investment Ownership Percentage	26.90%		26.90%
Windset [Member] | Apio [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Payments to Acquire Investments			11,000,000
Windset [Member] | Common Stock [Member] | Apio [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investment In Non Public Company Shares			68	201
Payments to Acquire Investments				201
Windset [Member] | Junior Preferred Shares [Member] | Apio [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investment In Non Public Company Shares			51,211
Windset [Member] | Senior A Preferred Stock [Member] | Apio [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investment In Non Public Company Shares				150,000
Payments to Acquire Investments				15,000,000
Windset [Member] | Senior B Preferred Stock [Member] | Apio [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investment In Non Public Company Shares					70,000
Payments to Acquire Investments					$7,000,000
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Ophthalmic [Member] | HA Based Biomaterials [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Concentration Risk, Percentage						60.00%
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Orthopedic [Member] | HA Based Biomaterials [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Concentration Risk, Percentage						20.00%

Note_1_Organization_Basis_of_P3

Note 1 - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Summary of Significant Unobservable Inputs Used in Discounted Cash Flow Models (Details)	6 Months Ended	12 Months Ended
	Nov. 30, 2014	25-May-14
Revenue growth rates	4.00%	4.00%
Expense growth rates	4.00%	4.00%
Income tax rates	15.00%	15.00%
Maximum [Member]
Discount rates	22.00%	22.00%
Minimum [Member]
Discount rates	16.00%	16.00%

Note_1_Organization_Basis_of_P4

Note 1 - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Assumptions Used in Discounted Cash Flow Models (Details) (USD $)	Nov. 30, 2014
In Millions, unless otherwise specified
10% increase in revenue growth rates	$4.90
10% increase in expense growth rates	-4.1
10% increase in discount rates	($0.70)

Note_1_Organization_Basis_of_P5

Note 1 - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Summary of Fair Value of Assets and Liabilities Measure on Recurring Basis (Details) (USD $)	Nov. 30, 2014	25-May-14
In Thousands, unless otherwise specified
Fair Value, Inputs, Level 2 [Member]
Interest rate swap	$9	$44
Total	9	44
Fair Value, Inputs, Level 3 [Member]
Investment in private company	59,000	39,600
Total	$59,000	$39,600

Note_1_Organization_Basis_of_P6

Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies - Revenue Arrangements (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014	Nov. 24, 2013	Nov. 30, 2014	Nov. 24, 2013
Revenue	$132,665	$120,026	$266,279	$229,505
Revenue from License Fees, R&D Contracts and Royalties/Profit Sharing [Member]
Revenue	423	143	635	201
Revenue from Multiple Element Arrangements [Member]
Revenue	372	1,941	947	2,563
Revenue Recorded Upon Acceptance in Foreign Port [Member]
Revenue	22,106	22,940	48,693	44,329
Revenue Recorded Upon Shipment [Member]
Revenue	109,764	95,002	216,004	182,412
Fair Value, Inputs, Level 1 [Member]
Revenue	132,665			229,505
Fair Value, Inputs, Level 2 [Member]
Revenue		120,026
Fair Value, Inputs, Level 3 [Member]
Revenue			$266,279

Note_2_Investments_in_Nonpubli1

Note 2 - Investments in Non-public Companies (Details Textual) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended
	Nov. 30, 2014	Nov. 24, 2013	Nov. 30, 2014	Nov. 24, 2013	30-May-10	Feb. 15, 2011	Jun. 30, 2010	Jul. 15, 2014	Oct. 29, 2014	25-May-14	Dec. 31, 2005
Schedule of Investments [Abstract]
Payments to Acquire Investments			$18,000,000
Investment Income, Dividend	321,000	281,000	602,000	563,000
Aesthetic Sciences [Member]
Schedule of Investments [Abstract]
Long-term Investments	793,000		793,000							793,000	1,800,000
Other than Temporary Impairment Losses, Investments					1,000,000
Windset [Member]
Schedule of Investments [Abstract]
Investment Ownership Percentage	26.90%		26.90%					26.90%
Preferred Stock, Dividend Rate, Percentage						7.50%
Change In Market Value Of Investment In Company	1,200,000	2,300,000	1,400,000	7,700,000
Development Fee							100,000
Annual Minimum License Fees							150,000
License Agreement, Number of Products	2		2
Annual License Fee Percentage							3.00%
Windset [Member] | Apio [Member]
Schedule of Investments [Abstract]
Payments to Acquire Investments								11,000,000
Preferred Stock, Liquidation Preference, Value	20,100,000		20,100,000
Windset [Member] | Common Stock [Member] | Apio [Member]
Schedule of Investments [Abstract]
Investment In Non Public Company Shares						201		68
Payments to Acquire Investments						201
Windset [Member] | Junior Preferred Shares [Member] | Apio [Member]
Schedule of Investments [Abstract]
Investment In Non Public Company Shares								51,211
Preferred Stock, Liquidation Preference, Value	5,100,000		5,100,000
Windset [Member] | Senior A Preferred Stock [Member] | Apio [Member]
Schedule of Investments [Abstract]
Investment In Non Public Company Shares						150,000
Payments to Acquire Investments						15,000,000
Preferred Stock, Liquidation Preference, Value	15,000,000		15,000,000
Windset [Member] | Senior B Preferred Stock [Member] | Apio [Member]
Schedule of Investments [Abstract]
Investment In Non Public Company Shares									70,000
Payments to Acquire Investments									7,000,000
Preferred Stock, Dividend Rate, Percentage									7.50%
Windset [Member] | Senior B Preferred Stock [Member] | Apio [Member] | First Anniversary [Member]
Schedule of Investments [Abstract]
Investments, Value of Shares with Put Option									1,500,000
Windset [Member] | Senior B Preferred Stock [Member] | Apio [Member] | Second Anniversary [Member]
Schedule of Investments [Abstract]
Investments, Value of Shares with Put Option									2,750,000
Windset [Member] | Senior B Preferred Stock [Member] | Apio [Member] | Third Anniversary [Member]
Schedule of Investments [Abstract]
Investments, Value of Shares with Put Option									$2,750,000

Note_3_Stockbased_Compensation2

Note 3 - Stock-based Compensation (Details Textual) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	1.9
Employee Stock Option [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 182 days
Restricted Stock Units (RSUs) [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 146 days

Recovered_Sheet1

Note 3 - Stock-Based Compensation - Summary of Stock-Based Compensation by Income Statement Line Item (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 24, 2013	Nov. 30, 2014	Nov. 24, 2013
Stock-based compensation expense	$350	$361	$748	$639
Research and Development Expense [Member]
Stock-based compensation expense	8		20	14
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	342	361	728	625
Employee Stock Option [Member]
Stock-based compensation expense	122	177	255	285
Restricted Stock Units (RSUs) [Member]
Stock-based compensation expense	$228	$184	$493	$354

Note_4_Diluted_Net_Income_Per_2

Note 4 - Diluted Net Income Per Share (Details Textual)	3 Months Ended		6 Months Ended
	Nov. 30, 2014	Nov. 24, 2013	Nov. 30, 2014	Nov. 24, 2013
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	321,500	342,500	329,056	273,882

Note_4_Diluted_Net_Income_Per_3

Note 4 - Diluted Net Income Per Share - Diluted Net Income Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Nov. 30, 2014	Nov. 24, 2013	Nov. 30, 2014	Nov. 24, 2013
Net income	$3,223	$3,451	$5,576	$8,203
Weighted average shares for basic net income per share (in shares)	26,864	26,571	26,852	26,512
Stock options and restricted stock units (in shares)	450	499	441	569
Weighted average shares for diluted net income per share (in shares)	27,314	27,070	27,293	27,081
Diluted net income per share (in dollars per share)	$0.12	$0.13	$0.20	$0.30

Note_5_Income_Taxes_Details_Te

Note 5 - Income Taxes (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Nov. 30, 2014	Nov. 24, 2013	Nov. 30, 2014	Nov. 24, 2013	25-May-14
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$1,785,000	$1,874,000	$3,086,000	$4,349,000
Effective Income Tax Rate Reconciliation, Percent			36.00%	35.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			35.00%
Unrecognized Tax Benefits	945,000		945,000		1,000,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$759,000		$759,000		$807,000
Domestic Tax Authority [Member] | Earliest Tax Year [Member]
Income Tax Disclosure [Abstract]
Open Tax Year			1997
State and Local Jurisdiction [Member] | Earliest Tax Year [Member]
Income Tax Disclosure [Abstract]
Open Tax Year			1998

Note_6_Inventories_Inventories

Note 6 - Inventories - Inventories (Details) (USD $)	Nov. 30, 2014	25-May-14
In Thousands, unless otherwise specified
Finished goods	$14,304	$11,111
Raw materials	12,089	10,376
Work in progress	4,047	3,248
Total	$30,440	$24,735

Note_7_Debt_Details_Textual

Note 7 - Debt (Details Textual) (USD $)	6 Months Ended	1 Months Ended			3 Months Ended		6 Months Ended
	Nov. 30, 2014	Apr. 23, 2012	Jul. 17, 2014	23-May-12	Nov. 30, 2014	Nov. 24, 2013	Nov. 24, 2013	25-May-14	Nov. 24, 2014	Aug. 28, 2014
Debt Disclosure [Abstract]
Long-term Debt	$42,225,000				$42,225,000			$34,372,000
Letters of Credit Outstanding, Amount				3,500,000
Annual Remarketing Fee Percentage	0.13%
Annual Letter of Credit Fee Percentage	0.75%
Number of Financing Agreements				2
Apio [Member]
Debt Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity		25,000,000
Line of Credit Facility, Remaining Borrowing Capacity	31,100,000				31,100,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.38%
Long-term Line of Credit	5				5			0
Minimum Fixed Charge Coverage Ratio	1.1
Line of Credit Facility Borrowing Availability Threshold	12,000,000				12,000,000
Capitalized Loan Origination Fees	293,000
Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums	1,200,000				1,200,000			1,000,000
Apio [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Disclosure [Abstract]
Debt Instrument, Basis Spread on Variable Rate		2.00%
Lifecore [Member]
Debt Disclosure [Abstract]
Minimum Fixed Charge Coverage Ratio	1.1
Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums	73,000				73,000			98,000
Minimum Quick Ratio	1.25
Minimum Tangible Net Worth	29,000,000				29,000,000
Capital Equipment Loan [Member] | Apio [Member]
Debt Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity			25
Long-term Line of Credit									4,100,000	7,100,000
Debt Instrument, Term			5 years
Line of Credit Facility Amortization Period			7 years
Debt Instrument, Interest Rate, Stated Percentage									3.74%	3.68%
Amendment [Member] | Apio [Member]
Debt Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity			40,000,000
Amendment [Member] | Apio [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Disclosure [Abstract]
Debt Instrument, Basis Spread on Variable Rate			1.75%
Term Loan [Member]
Debt Disclosure [Abstract]
Long-term Debt				12,000,000
Debt Instrument, Periodic Payment, Principal				250,000
Term Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Disclosure [Abstract]
Debt Instrument, Basis Spread on Variable Rate				2.00%
Working Capital Line Of Credit [Member]
Debt Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity				10,000,000
Line of Credit Facility, Remaining Borrowing Capacity	7,800,000				7,800,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.00%
Long-term Line of Credit	0				0			0
Line of Credit Facility, Expiration Period				1 year
Working Capital Line Of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Disclosure [Abstract]
Debt Instrument, Basis Spread on Variable Rate				1.85%
Apio [Member] | Amortization of Loan Origination Fees [Member]
Debt Disclosure [Abstract]
Interest Expense, Other	97,000				51,000	47,000	94,000
Lifecore [Member] | Amortization of Loan Origination Fees [Member]
Debt Disclosure [Abstract]
Interest Expense, Other	$26,000				$13,000	$13,000	$26,000

Note_7_Debt_Longterm_Debt_Deta

Note 7 - Debt - Long-term Debt (Details) (USD $)	Nov. 30, 2014	25-May-14
Long-term Debt	$42,225,000	$34,372,000
Less current portion	-7,550,000	-6,055,000
Long-term portion	34,675,000	28,317,000
Capital Equipment Loan 1 [Member]
Long-term Debt	8,578,000	9,430,000
Capital Equipment Loan 2 [Member]
Long-term Debt	6,924,000
Capital Equipment Loan 3 [Member]
Long-term Debt	4,124,000
Industrial Revenue Bonds [Member]
Long-term Debt	2,440,000	2,805,000
Real Estate Loan [Member]
Long-term Debt	15,659,000	16,137,000
Term Loan [Member]
Long-term Debt	$4,500,000	$6,000,000

Note_7_Debt_Longterm_Debt_Deta1

Note 7 - Debt - Long-term Debt (Details) (Parentheticals) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014	25-May-14
Capital Equipment Loan 1 [Member]
Monthly principal and interest payments	$175,356	$175,356
Fixed interest rate	4.39%	4.39%
Capital Equipment Loan 2 [Member]
Monthly principal and interest payments	95,120
Fixed interest rate	3.68%
Capital Equipment Loan 3 [Member]
Monthly principal and interest payments	55,828
Fixed interest rate	3.74%
Industrial Revenue Bonds [Member]
Fixed interest rate	0.25%	0.28%
Real Estate Loan [Member]
Monthly principal and interest payments	133,060	133,060
Fixed interest rate	4.02%	4.02%
Term Loan [Member]
Monthly principal and interest payments	$250,000	$250,000
Fixed interest rate	2.00%	2.00%

Note_8_Derivative_Financial_In1

Note 8 - Derivative Financial Instruments (Details Textual) (USD $)	Nov. 30, 2014	25-May-14	30-May-10
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Asset, Notional Amount			$20,000,000
Derivative Liability, Fair Value, Gross Liability	9,000	44,000
Derivative, Swaption Interest Rate			4.24%
Derivative, Notional Amount			$20,000,000

Note_9_Related_Party_Details_T

Note 9 - Related Party (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Nov. 30, 2014	Nov. 24, 2013	Nov. 30, 2014	Nov. 24, 2013	25-May-14
Related Party Transactions [Abstract]
Accounts Receivable, Related Parties, Current	$162,000		$162,000		$304,000
Windset [Member]
Related Party Transactions [Abstract]
Revenue from Related Parties	161,000	16,000	195,000	21,000
Accounts Receivable, Related Parties, Current	162,000		162,000		304,000
Accounts Payable, Related Parties	332,000		332,000		134,000
Cost of Sales [Member] | Windset [Member]
Related Party Transactions [Abstract]
Related Party Transaction, Purchases from Related Party	$297,000	$431,000	$708,000	$812,000

Note_10_Stockholders_Equity_De

Note 10 - Stockholders' Equity (Details Textual) (USD $)	3 Months Ended	6 Months Ended
	Nov. 30, 2014	Nov. 30, 2014	Jul. 14, 2010
Stockholders' Equity Note [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	30,000
Common Stock, Capital Shares Reserved for Future Issuance	3,100,000	3,100,000
Stock Repurchase Program, Authorized Amount			$10,000,000
Stock Repurchased During Period, Shares	0	0
Restricted Stock Units (RSUs) [Member]
Stockholders' Equity Note [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		43,752

Note_10_Stockholders_Equity_Co

Note 10 - Stockholders' Equity - Consolidated Statements of Changes in Stockholders' Equity (Details) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Nov. 30, 2014
Common Stock Shares
Balance at May 25, 2014 (in shares)	26,815,253
Stock options exercised, net of shares tendered (in shares)	31,235
Vested restricted stock units, net of shares tendered (in shares)	29,496
Balance at November 30, 2014 (in shares)	26,875,984
Balance at May 25, 2014	$27
Balance at November 30, 2014	27
Additional Paid-in Capital
Balance at May 25, 2014	131,488
Stock options exercised, net of shares tendered	100
Taxes paid by Company for stock swaps and restricted stock units	-12
Stock-based compensation expense	748
Tax benefit from stock based compensation	36
Balance at November 30, 2014	132,360
Retained Earnings
Balance at May 25, 2014	71,554
Net income	5,576
Balance at November 30, 2014	77,130
Non-controlling Interest
Balance at May 25, 2014	1,692
Non-controlling interest in net income	95
Distributions to non-controlling interest	-196
Balance at November 30, 2014	$1,591

Note_11_Business_Segment_Repor2

Note 11 - Business Segment Reporting (Details Textual) (Sales Revenue, Net [Member], Customer Concentration Risk [Member])	6 Months Ended
	Nov. 30, 2014	Nov. 24, 2013
Segment Reporting [Abstract]
Concentration Risk, Percentage	44.00%	43.00%
Number of Operating Segments	3
Entity Wide Revenue Major Customer Number	5	5
Food Products Technology [Member]
Segment Reporting [Abstract]
Entity Wide Revenue Major Customer Number	2	2
Customer 1 [Member] | Food Products Technology [Member]
Segment Reporting [Abstract]
Concentration Risk, Percentage	20.00%	20.00%
Customer 2 [Member] | Food Products Technology [Member]
Segment Reporting [Abstract]
Concentration Risk, Percentage	11.00%	11.00%

Note_11_Business_Segment_Repor3

Note 11 - Business Segment Reporting - Sales by Geograhic Area (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 24, 2013	Nov. 30, 2014	Nov. 24, 2013
INDONESIA
Segment sales	$4.90	$2.40	$6.50	$4.90
BELGIUM
Segment sales		0.8		2
CHINA
Segment sales	2.9	3.7	7.3	5.3
JAPAN
Segment sales	2.3	2.1	5.1	5.3
CANADA
Segment sales	17.5	10.2	35.2	19.6
TAIWAN, PROVINCE OF CHINA
Segment sales	9.4	12.6	25.6	24.6
All Other Countries [Member]
Segment sales	$4.60	$4.90	$8.30	$10.20

Note_11_Business_Segment_Repor4

Note 11 - Business Segment Reporting - Operations by Business Segment (Details) (USD $)	3 Months Ended		6 Months Ended
	Nov. 30, 2014	Nov. 24, 2013	Nov. 30, 2014	Nov. 24, 2013
Net sales	$132,665,000	$120,026,000	$266,279,000	$229,505,000
International sales	41,600,000	36,651,000	87,972,000	71,895,000
Gross profit	15,666,000	13,734,000	29,854,000	26,266,000
Net income (loss)	3,223,000	3,451,000	5,576,000	8,203,000
Depreciation and amortization	1,830,000	1,945,000	3,343,000	3,787,000
Investment Income, Dividend	321,000	281,000	602,000	563,000
Interest income	91,000	46,000	184,000	105,000
Interest expense	472,000	436,000	855,000	867,000
Income tax expense	1,785,000	1,874,000	3,086,000	4,349,000
Corporate Segment [Member]
Net sales	162,000	128,000	262,000	186,000
Gross profit	161,000	69,000	261,000	127,000
Net income (loss)	-991,000	108,000	-1,013,000	-2,306,000
Depreciation and amortization	31,000	36,000	62,000	71,000
Interest income	9,000		20,000
Income tax expense	1,252,000	36,000	1,890,000	2,034,000
Food Export [Member]
Net sales	22,106,000	23,031,000	48,703,000	44,430,000
International sales	22,106,000	22,940,000	48,693,000	44,329,000
Gross profit	1,550,000	1,820,000	2,736,000	3,025,000
Net income (loss)	582,000	727,000	853,000	1,003,000
Depreciation and amortization	1,000	1,000	2,000	2,000
Income tax expense	95,000	205,000	139,000	283,000
Food Products Technology [Member]
Net sales	102,079,000	88,090,000	202,185,000	167,526,000
International sales	17,760,000	10,345,000	35,911,000	19,823,000
Gross profit	11,151,000	8,220,000	23,005,000	17,101,000
Net income (loss)	3,644,000	2,005,000	7,290,000	9,271,000
Depreciation and amortization	1,237,000	1,304,000	2,247,000	2,526,000
Investment Income, Dividend	321,000	281,000	602,000	563,000
Interest income	15,000	2,000	26,000	5,000
Interest expense	425,000	356,000	763,000	732,000
Income tax expense	440,000	1,461,000	1,310,000	1,966,000
HA Based Biomaterials [Member]
Net sales	8,318,000	8,777,000	15,129,000	17,363,000
International sales	1,734,000	3,366,000	3,368,000	7,743,000
Gross profit	2,804,000	3,625,000	3,852,000	6,013,000
Net income (loss)	-12,000	611,000	-1,554,000	235,000
Depreciation and amortization	561,000	604,000	1,032,000	1,188,000
Interest income	67,000	44,000	138,000	100,000
Interest expense	47,000	80,000	92,000	135,000
Income tax expense	($2,000)	$172,000	($253,000)	$66,000